The recent explosion of biological data from genomics, proteomics and interactomics research has provided invaluable new information into how disease occurs at the DNA, protein and systems levels. However, a new and imposing technical bottleneck has also thereby been created. Because recombinant protein production tools do not match the sophistication and complexity of living organisms, the provision of the increasingly complex biological specimens identified, in assayable or druggable form, has become a serious challenge. This technology gap is considerably hampering progress and success in academic and industrial research and development.

Based on the leading expertise and innovative drive of the partners, ComplexINC will address this urgent and imposing bottleneck, by providing new and sophisticated tools and technologies, to overcome the challenge of complex biologics production in drug discovery and therapy for the 21st century.